Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CROC

Financiado

The natural K, Fe, and Cu isotopic response to Pt-based chemotherapeutic drug re...

The natural K, Fe, and Cu isotopic response to Pt-based chemotherapeutic drug resistance in ovarian cancer Cancer is the second leading cause of death globally and in the EU, and was responsible for an estimated one in six deaths in 2018. Early diagnosis plays an important role in determining cancer treatment outcomes, but the diagnosi... ver más

31/08/2026

UGent

176K€

Presupuesto del proyecto: 176K€

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-07-12

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UGent

175.92K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2015-65175-R RESISTENCIA MEDIADA POR EL MICROAMBIENTE EN GLIOBLASTOMA: CA... 145K€ Cerrado

MATADOR MAmmary chemoresistant Tumor deAth by Directed cell ORientat... 150K€ Cerrado

PID2019-111256RB-I00 TERAPIA ANTITUMORAL ADAPTATIVA USANDO DATOS TRANSVERSALES Y... 72K€ Cerrado

MR O MICS Unravelling Tumour Biology In Ovarian Cancer With Precision... 1M€ Cerrado

STRONGER What doesn’t kill you: primed and adaptive mechanisms of tre... 2M€ Cerrado

CROC Unravelling ChemoResistance mechanisms and improving first-l... 215K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2023-07-12
Fecha Fin: 2026-08-31

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 176K€

Descripción del proyecto Cancer is the second leading cause of death globally and in the EU, and was responsible for an estimated one in six deaths in 2018. Early diagnosis plays an important role in determining cancer treatment outcomes, but the diagnosis of ovarian cancer poses significant challenges; the routine screening of asymptomatic average-risk women is not recommended by any professional society. Chemotherapy using Pt-based compounds (e.g. carboplatin, cisplatin) is a standard treatment, but tumours that are initially responsive may develop chemoresistance, resulting in treatment failure. The ability to predict patient response towards post-operative treatments would allow for ineffective treatments and harmful side effects to be avoided and alternative treatments to be commenced at earlier stages. Several mechanisms underlying tumour cell resistance have been identified so far, including the altered expression of ion channels (Na, Mg, K, and Ca) and Fe-, Cu-, and Zn-binding proteins, but these remain poorly understood and it is unclear whether they can be exploited as markers of resistance. To that end, I will apply high-precision isotopic analysis by multicollector-inductively coupled plasma-mass spectrometry to Fe, K, and Cu to understand processes and determine whether changes in the natural abundances of these isotopes are associated with the development of resistance to Pt-based chemotherapeutic drugs in high-grade serous ovarian cancer (HGSOC), the deadliest gynaecological cancer, which accounts for ~70% of ovarian malignancies. Deviations in natural isotopic abundances signal biochemical changes (affecting the extent of isotopic fractionation accompanying some biochemical processes) occurring as a result of a disease in a systematic and reliable way. Through ovarian cancer cell line, tumour spheroid, and HGSOC patient plasma experiments, I aim to develop a revolutionary, minimally-invasive prognostic marker of Pt-based chemotherapeutic drug resistance.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores